Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 14/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81232 | 1.00 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775519 | 1.00 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775459 | 1.00 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17748194 | 1.00 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18423632 | 0.98 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL29775522 | 0.98 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19307744 | 0.98 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81657 | 0.98 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL82531 | 0.98 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17748203 | 0.95 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| EP-3372281-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2021-07-07 | — | — | EP | disclosed |
| US-10927129-B2 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | SHINOGI & CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-20200339598-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10696636-B2 | Process for the preparation of HIV integrase inhibitors | LUPIN LIMITED (IN) | 2020-06-30 | — | — | US | disclosed |
| US-20200172487-A1 | PROCESS FOR THE PREPARATION OF HIV INTEGRASE INHIBITORS | LUPIN MANUFACTURING SOLUTIONS LIMITED (IN) | 2020-06-04 | — | — | US | disclosed |
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2019-09-19 | — | — | US | disclosed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2330902-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120209000-A1 | CHEMICAL COMPOUNDS | JOHNS BRIAN ALVIN (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2465858-A1 | Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative | Glaxosmithkline LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8183372-B2 | Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines | SHIONOGI & CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2011-11-17 | — | — | US | disclosed |
| US-20110124598-A1 | CHEMICAL COMPOUNDS | VIIV HEALTHCARE COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927129-B2 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | DUT, DPYD, IMPDH1 | SLC22A2 2499/4885CYP3A4 448/4885TMEM97 2196/4885 |
| US-10696636-B2 | Process for the preparation of HIV integrase inhibitors | XDH, APOBEC3C, APOBEC3G | SLC22A2 3800/4885CYP3A4 5/4885TMEM97 1897/4885 |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | SLC22A2 4555/4885CYP3A4 230/4885TMEM97 4128/4885 |
| US-20200172487-A1 | PROCESS FOR THE PREPARATION OF HIV INTEGRASE INHIBITORS | XDH, APOBEC3C, APOBEC3G | SLC22A2 3800/4885CYP3A4 5/4885TMEM97 1897/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | TYMP, TYMS, POLA1 | SLC22A2 4565/4885CYP3A4 234/4885TMEM97 4135/4885 |
| US-20200339598-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2820/4885CYP3A4 32/4885TMEM97 3581/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | SLC22A2 4476/4885CYP3A4 527/4885TMEM97 4291/4885 |
| US-20120209000-A1 | CHEMICAL COMPOUNDS | CYP3A5, CYP3A7, CYP11B2 | SLC22A2 1549/4885CYP3A4 5/4885TMEM97 3579/4885 |
| US-20110282055-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | CDK2, CDK6, BRD4 | SLC22A2 4314/4885CYP3A4 191/4885TMEM97 4340/4885 |
| US-20110124598-A1 | CHEMICAL COMPOUNDS | APRT, API5, REL | SLC22A2 2639/4885CYP3A4 60/4885TMEM97 4076/4885 |
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NR4A2, NR4A3 | SLC22A2 3802/4885CYP3A4 22/4885TMEM97 2054/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.